Doxofylline: Difference between revisions
Kiran Singh (talk | contribs) (Created page with "{{Drugbox | verifiedrevid = 444222727 | IUPAC_name = 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione | image = Doxofylline.png <!--Clinical data--> | tradename = |...") |
m (Protected "Doxofylline": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 2: | Line 2: | ||
| verifiedrevid = 444222727 | | verifiedrevid = 444222727 | ||
| IUPAC_name = 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione | | IUPAC_name = 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione | ||
| image = Doxofylline.png | | image =Doxofylline.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| Line 47: | Line 47: | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist|2}} | ||
* Dali Shukla, Subhashis Chakraborty, Sanjay Singh & Brahmeshwar Mishra. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy. 2009; 10(14): 2343-2356, DOI 10.1517/14656560903200667, PMID 19678793 | * Dali Shukla, Subhashis Chakraborty, Sanjay Singh & Brahmeshwar Mishra. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy. 2009; 10(14): 2343-2356, DOI 10.1517/14656560903200667, PMID 19678793 | ||
| Line 56: | Line 56: | ||
[[Category:Xanthines]] | [[Category:Xanthines]] | ||
[[Category:Phosphodiesterase inhibitors]] | [[Category:Phosphodiesterase inhibitors]] | ||
Latest revision as of 20:14, 18 August 2015
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C11H14N4O4 |
| Molar mass | 266.25 g/mol |
| 3D model (JSmol) | |
| |
| (verify) | |
|
WikiDoc Resources for Doxofylline |
|
Articles |
|---|
|
Most recent articles on Doxofylline Most cited articles on Doxofylline |
|
Media |
|
Powerpoint slides on Doxofylline |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Doxofylline at Clinical Trials.gov Clinical Trials on Doxofylline at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Doxofylline
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Doxofylline Discussion groups on Doxofylline Patient Handouts on Doxofylline Directions to Hospitals Treating Doxofylline Risk calculators and risk factors for Doxofylline
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Doxofylline |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Doxofylline (INN), (also known as doxophylline) is a xanthine derivative drug used in the treatment of asthma.[1]
It has antitussive[citation needed] and bronchodilator[2] effects, and acts as a phosphodiesterase inhibitor.[3]
In animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects.[4]
Unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase.[1]
References
- ↑ 1.0 1.1 Cirillo R, Barone D, Franzone JS (1988). "Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors". Arch Int Pharmacodyn Ther. 295: 221–37. PMID 3245738.
- ↑ Poggi R, Brandolese R, Bernasconi M, Manzin E, Rossi A (October 1989). "Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure". Chest. 96 (4): 772–8. doi:10.1378/chest.96.4.772. PMID 2791671.
- ↑ Dini FL, Cogo R (2001). "Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects". Curr Med Res Opin. 16 (4): 258–68. doi:10.1185/030079901750120196. PMID 11268710.
- ↑ Sankar J, Lodha R, Kabra SK (March 2008). "Doxofylline: The next generation methylxanthine". Indian J Pediatr. 75 (3): 251–4. doi:10.1007/s12098-008-0054-1. PMID 18376093.
- Dali Shukla, Subhashis Chakraborty, Sanjay Singh & Brahmeshwar Mishra. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy. 2009; 10(14): 2343-2356, DOI 10.1517/14656560903200667, PMID 19678793
Template:Asthma and copd rx Template:Phosphodiesterase inhibitors
- Pages with script errors
- Pages with reference errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- All articles with unsourced statements
- Articles with unsourced statements from December 2008
- Articles with invalid date parameter in template
- Drug
- Xanthines
- Phosphodiesterase inhibitors